ethacrynic acid

Absorption: Well absorbed after oral administration. IV administration results in complete bioavailability.

Distribution: Unknown.

Protein Binding: >90%.

Metabolism/Excretion: 35–40% metabolized by liver; 60% eliminated unchanged by kidneys.

Half-Life: 2–4 hr.

Time/Action Profile ⬆ ⬇

(diuretic effect)

ROUTE	ONSET	PEAK	DURATION
PO	30 min	2 hr	6–8 hr
IV	5 min	30 min	2 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Hypersensitivity;
Hepatic coma or anuria.

Use Cautiously in:

Severe liver disease (may precipitate hepatic coma; concurrent use with potassium-sparing diuretics may be necessary);
Electrolyte depletion;
Diabetes mellitus;
Increasing azotemia;
OB: Safety not established;
Geri: Possible risk of side effects at usual doses, especially hypotension and electrolyte imbalance.

Adv. Reactions/Side Effects ⬆ ⬇

CV: hypotension

Derm: rash

EENT: hearing loss, tinnitus

Endo: hyperglycemia, hyperuricemia

F and E: dehydration, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, hypovolemia, metabolic alkalosis, hypocalcemia

GI: abdominal pain, anorexia, diarrhea, dry mouth, dysphagia, nausea, vomiting

GU: azotemia, excessive urination, hematuria

Hemat: AGRANULOCYTOSIS, neutropenia, thrombocytopenia

Neuro: confusion, fatigue, headache, nervousness, vertigo

Misc: fever

Interactions ⬆ ⬇

Drug-drug:

↑hypotension with antihypertensives, nitrates, or acute ingestion of alcohol.
↑risk of hypokalemia with other diuretics, amphotericin B, stimulant laxatives, and corticosteroids.
Hypokalemia may ↑ risk of digoxin toxicity and ↑ risk of arrhythmia in patients taking drugs that prolong the QT interval.
↓lithium excretion, may cause lithium toxicity.
↑risk of ototoxicity with aminoglycosides.
May ↑ the effectiveness of warfarin,.
NSAIDS↓ effects of ethacrynic acid.

Route/Dosage ⬆ ⬇

PO (Adults ): 50–100 mg/day in 1–2 divided doses; may ↑ dose by 25–50 mg every few days until desired response (maximum dose = 400 mg/day).
PO (Children >1 mo): 1 mg/kg/dose once daily; may be ↑ every 2–3 days to a maximum of 3 mg/kg/day.
IV (Adults ): 0.5–1 mg/kg/dose (maximum = 100 mg/dose); may repeat dose every 8–12 hr if needed.
IV (Children >1 mo): 1 mg/kg/dose, may repeat dose if indicated q 8–12 hr.

Availability ⬆ ⬇

(Generic available)

Tablet: 25 mg
Injection: 50 mg/vial

Assessment ⬆ ⬇

Assess fluid status. Monitor daily weight, intake and output ratios, amount and location of edema, lung sounds, skin turgor, and mucous membranes. Notify health care professional if thirst, dry mouth, lethargy, weakness, hypotension, or oliguria occurs.
Monitor BP and pulse before and during administration. Monitor frequency of prescription refills to determine compliance.
Assess patients receiving digoxin for anorexia, nausea, vomiting, muscle cramps, paresthesia, and confusion. Patients taking digoxin are at increased risk of digoxin toxicity because of the potassium-depleting effect of the diuretic. Potassium supplements or potassium-sparing diuretics may be used concurrently to prevent hypokalemia.
Assess patient for tinnitus and hearing loss. Audiometry is recommended for patients receiving prolonged high-dose IV therapy. Hearing loss is most common after rapid or high-dose IV administration in patients with decreased renal function or those taking other ototoxic drugs.
Geri: Diuretic use is associated with increased risk for falls in older adults. Assess fall risk and implement fall prevention strategies.

Lab Test Considerations:

Monitor electrolytes, renal and hepatic function, serum glucose, and uric acid levels before and periodically during therapy. May cause ↓ serum sodium, potassium, calcium, and magnesium concentrations. May also cause ↑ BUN, serum glucose, creatinine, and uric acid levels.

Implementation ⬆ ⬇

heparin
hydrocortisone sodium succinate
potassium chloride
vitamin B complex with C

If administering twice daily, give last dose no later than 5 pm to minimize disruption of sleep cycle.
Intermittent Infusion: Dilute vial in 25–50 mL of D5W, D5/0.9% NaCl, 0.9% NaCl, or LR. Use reconstituted solution within 24 hr.
Rate: Administer at a rate not to exceed 10 mg/min to prevent ototoxicity. Use an infusion pump to ensure accurate dose.

Patient/Family Teaching ⬆ ⬇

Instruct patient to take ethacrynic acid as directed. Take missed doses as soon as possible; do not double doses.
- Caution patient to change positions slowly to minimize orthostatic hypotension. Caution patient that the use of alcohol, exercise during hot weather, or standing for long periods during therapy may enhance orthostatic hypotension.
- Instruct patient to consult health care professional regarding a diet high in potassium.See Food Sources for Specific Nutrients.
- Advise patient to obtain weight at the same time each day (preferably in the morning after urinating) and to keep a daily log of the results. Advise patient to contact health care professional of weight gain more than 3 lbs in one day.
- Advise patient to consult health care professional before taking OTC medication or herbal products concurrently with this therapy.
- Instruct patient to notify health care professional of medication regimen before treatment or surgery.
- Advise patient to contact health care professional immediately if muscle weakness, cramps, nausea, dizziness, numbness, or tingling of extremities occurs.
- Advise patients with diabetes to monitor blood glucose closely; may cause increased blood glucose levels.
- Emphasize the importance of routine follow-up examinations.
- Caution older patients or their caregivers about increased risk for falls. Suggest strategies for fall prevention.

Evaluation/Desired Outcomes ⬆ ⬇

Decrease in edema.
- Decrease in abdominal girth and weight.
- Increase in urinary output.

US Brand Names ⬆ ⬇

Code ⬆

NDC Code

0054- West-Ward Pharmaceuticals Corp.
- 0054-0415- Ethacrynic Acid
  - 0054-0415-25- 100 TABLET in 1 BOTTLE (0054-0415-25)

0054- West-Ward Pharmaceuticals Corp.
- 0054-0415- Ethacrynic Acid
  - 0054-0415-29- 500 TABLET in 1 BOTTLE (0054-0415-29)

25010- Aton Pharma, Inc.
- 25010-215- EDECRIN
  - 25010-215-15- 100 TABLET in 1 BOTTLE (25010-215-15)

42799- Edenbridge Pharmaceuticals, LLC
- 42799-405- Ethacrynic Acid
  - 42799-405-01- 100 TABLET in 1 BOTTLE (42799-405-01)

47781- Alvogen, Inc.
- 47781-497- Ethacrynic acid
  - 47781-497-01- 100 TABLET in 1 BOTTLE (47781-497-01)

49884- Par Pharmaceutical, Inc.
- 49884-276- Ethacrynic Acid
  - 49884-276-01- 100 TABLET in 1 BOTTLE (49884-276-01)

50228- ScieGen Pharmaceuticals Inc
- 50228-334- Ethacrynic Acid
  - 50228-334-01- 100 TABLET in 1 BOTTLE (50228-334-01)

50228- ScieGen Pharmaceuticals Inc
- 50228-334- Ethacrynic Acid
  - 50228-334-10- 1000 TABLET in 1 BOTTLE (50228-334-10)

50228- ScieGen Pharmaceuticals Inc
- 50228-334- Ethacrynic Acid
  - 50228-334-30- 30 TABLET in 1 BOTTLE (50228-334-30)

52817- TRUPHARMA LLC
- 52817-367- Ethacrynic acid
  - 52817-367-10- 100 TABLET in 1 BOTTLE (52817-367-10)

52817- TRUPHARMA LLC
- 52817-367- Ethacrynic acid
  - 52817-367-60- 60 TABLET in 1 BOTTLE (52817-367-60)

52817- TRUPHARMA LLC
- 52817-367- Ethacrynic acid
  - 52817-367-90- 90 TABLET in 1 BOTTLE (52817-367-90)

60429- Golden State Medical Supply, Inc.
- 60429-887- Ethacrynic Acid
  - 60429-887-01- 100 TABLET in 1 BOTTLE (60429-887-01)

68682- Oceanside Pharmaceuticals
- 68682-011- ethacrynic acid
  - 68682-011-10- 100 TABLET in 1 BOTTLE (68682-011-10)

69238- Amneal Pharmaceuticals NY LLC
- 69238-1126- Ethacrynic Acid
  - 69238-1126-1- 100 TABLET in 1 BOTTLE (69238-1126-1)

72134- Agnitio Inc.
- 72134-003- Ethacrynic acid
  - 72134-003-01- 100 TABLET in 1 BOTTLE (72134-003-01)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇